Moreover, TREM2 modulation by genetic ablation or monoclonal antibodies can remodel the myeloid cell immunosuppression within the TME, restrict tumor growth, and further improve immunotherapies such as anti-PD-1 therapy and NK cell-based therapy in mouse models with different tumor types (54–56). The gene discussed is TREM2; the disease is neoplasm.